6533b7dbfe1ef96bd1270a30
RESEARCH PRODUCT
Understanding symptoms in RYR1-Related Myopathies: A mixed-methods analysis based on participants' experience
M Sonia RazaqyarKatherine G. MeilleurMary M. CosgroveCarlos Capella-perisIrene C ChrismerJeffrey S ElliottAnna KuoMagalie Emile-backersubject
AdultMaleCoping (psychology)medicine.medical_specialtyWeaknessMEDLINEPainQualitative propertyArticleHealth administrationlaw.inventionInterviews as Topic03 medical and health sciences0302 clinical medicineDouble-Blind MethodMuscular DiseasesRandomized controlled triallawAdaptation PsychologicalHumansMedicine030212 general & internal medicineChildFatigueEsportsHealth economicsbusiness.industry030503 health policy & servicesPublic healthRyanodine Receptor Calcium Release ChannelMiddle AgedAcetylcysteineSocioeconomic FactorsQuality of LifeFemaleEducació físicamedicine.symptom0305 other medical sciencebusinessClinical psychologydescription
Background: In rare diseases such as ryanodine receptor 1-related myopathies (RYR1-RM), health-related quality of life (HRQoL) measures are critically important so clinicians and researchers can better understand what symptoms are most important to participants, with the ultimate goal of finding tangible solutions for them. Objectives: The main objective of this study was to characterize symptoms in individuals with RYR1-RM to inform future research. A secondary objective of this study was to analyze positive and negative sentiments regarding symptoms and treatment effects post N-acetylcysteine (NAC) administration in individuals with RYR1-RM. Methods: The study used a mixed-methods design applying methodological triangulation. Qualitative data were collected via semi-structured interviews at three visits to characterize symptoms in individuals with RYR1-RM and to analyze treatment effects. Qualitative data were then transformed into quantitative results to measure the frequency with which each symptom was mentioned by participants. Results: A total of 12 symptoms were identified as areas of interest to participants with RYR1-RM, highlighting fatigue and weakness as key symptoms. Data transformation categorized more than 1000 citations, reporting a greater number of positive comments for post-intervention interviews than for baseline and pre-intervention visits and that NAC group participants stated more positive comments regarding treatment effect than did the placebo group. Conclusions: We present a comprehensive characterization of symptoms in RYR1-RM and how those symptoms influence HRQoL. Furthermore, the introduction of mixed methods may be a valuable way to better understand patient-centered data in rare diseases to support affected individuals in coping with their symptoms.
year | journal | country | edition | language |
---|---|---|---|---|
2020-01-01 |